GO:0007265 Ras protein signal transduction: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007265 (Ras protein signal transduction) is defined as an intracellular signaling cassette in which a small monomeric GTPase of the Ras subfamily relays a signal.
• The core mechanism is a GTP-dependent molecular switch: Ras cycles between an inactive GDP-bound state and an active GTP-bound state to engage downstream effectors such as RAF.
• The best-characterized Ras effector route is the RAS-RAF-MEK-ERK MAPK cascade, which controls proliferation, differentiation and survival.
• Ras signaling is deregulated in many human cancers and in developmental disorders such as Noonan syndrome, making it a major therapeutic target.
• Ras proteins also intersect with redox biology, including superoxide generation, linking Ras signal transduction to oxidative signaling.
• CRISPR-based knockout, point-mutation, knock-in and overexpression models are central tools for dissecting Ras pathway causality and drug response.
Description
Ras protein signal transduction (GO:0007265) is a biological process in which a small monomeric GTPase of the Ras subfamily relays an intracellular signal. Ras proteins act as molecular switches that cycle between an inactive GDP-bound conformation and an active GTP-bound conformation, allowing them to transmit signals from activated cell-surface receptors to downstream effector pathways. This process is one of the most intensely studied signaling cassettes in cell biology because it sits at the nexus of growth factor signaling, cell proliferation and oncogenesis. The term is defined in QuickGO as an intracellular signaling cassette in which a small monomeric GTPase of the Ras subfamily relays a signal, and it is synonymous with Ras mediated signal transduction. The pathway is conserved across eukaryotes, and comparative work in divergent organisms such as Euglena gracilis has helped define the broader Ras superfamily GTPase framework. For researchers, GO:0007265 provides a precise ontology anchor for annotating genes, interpreting functional genomics screens and building mechanistic models of signal relay.
Ras protein signal transduction At A Glance
| GO ID | GO:0007265 |
|---|---|
| GO term | Ras protein signal transduction |
| Ontology | biological_process |
| Synonym | Ras mediated signal transduction |
| Definition | An intracellular signaling cassette in which a small monomeric GTPase of the Ras subfamily relays a signal. |
| Major function | Relay of intracellular signals through Ras-subfamily GTPase switches to downstream effectors. |
| Representative effectors | RAF kinases and the RAS-RAF-MEK-ERK MAPK cascade. |
| Representative regulators | Guanine nucleotide exchange factors and GTPase-activating proteins that control the GDP/GTP cycle. |
| Disease relevance | Deregulated in cancer and in RASopathy developmental syndromes such as Noonan syndrome. |
What Is GO:0007265?
In practical terms, GO:0007265 describes the intracellular signaling cassette in which a Ras-subfamily small GTPase receives an upstream cue and relays it to downstream effectors. The defining feature is the GTPase switch: Ras binds GTP when active and hydrolyzes it to GDP when inactive, and this cycle is coupled to effector engagement. The term is not a single molecule but a process, encompassing the activation, effector interaction and signal propagation steps mediated by Ras proteins. It is distinct from upstream receptor activation and from downstream kinase cascades, although it is mechanistically coupled to both.
Why Is Ras protein signal transduction Important in Cell Biology?
Ras protein signal transduction is important because it converts extracellular and receptor-proximal cues into defined intracellular outputs that control cell fate, proliferation and survival. Because the Ras switch is a central node, its dysregulation has broad consequences: activating lesions in Ras pathway components drive oncogenesis, while germline alterations cause developmental RASopathies such as Noonan syndrome. The pathway is also mechanistically informative, serving as a paradigm for how small GTPases achieve specificity and how effector selection shapes signaling output. Understanding GO:0007265 therefore supports both fundamental cell biology and translational efforts in oncology and precision medicine.
• Provides a mechanistic framework for how small GTPases relay signals inside cells.
• Controls proliferation, differentiation and survival through effector cascades such as RAS-RAF-MEK-ERK.
• Is a central driver of human cancer when constitutively activated.
• Underlies developmental disorders including Noonan syndrome through enhanced RAS-MAPK signaling.
• Connects to redox signaling, including superoxide-related pathways.
• Serves as a model system for GTPase switch biochemistry and effector specificity.
• Is a major target for small-molecule and biologic therapeutic strategies.
• Provides ontology annotations for functional genomics and pathway enrichment analyses.
• Is conserved across eukaryotes, enabling comparative studies.
• Supports CRISPR-based causal validation of pathway genes.
What Happens During Ras protein signal transduction?
Activation of the Ras GTPase switch
In simple terms: Ras is turned on when it picks up a GTP molecule.
Ras proteins function as binary switches that are inactive when bound to GDP and active when bound to GTP. Activation is promoted by guanine nucleotide exchange factors that accelerate release of GDP and allow GTP loading, while inactivation is catalyzed by GTPase-activating proteins that stimulate GTP hydrolysis. This cycle ensures that Ras signal transduction is temporally controlled and reversible.
Effector engagement and signal relay
In simple terms: Once active, Ras grabs downstream proteins and passes the signal on.
GTP-bound Ras engages downstream effectors, most prominently RAF kinases, thereby initiating the RAS-RAF-MEK-ERK MAPK cascade. Structural and biochemical studies have defined how Ras contacts RAF and how this interaction propagates the signal. Effector selection is a key determinant of signaling specificity within the Ras cassette.
MAPK cascade output
In simple terms: The signal travels through a chain of kinases to reach the nucleus.
The canonical output of Ras signal transduction is activation of the RAF-MEK-ERK module, which phosphorylates nuclear and cytoplasmic substrates to alter gene expression and cell behavior. Enhanced RAS-MAPK signaling is observed when pathway regulators are mutated, as in Noonan syndrome. This output links Ras directly to proliferation and differentiation programs.
Redox and non-canonical inputs
In simple terms: Ras signaling can also be influenced by reactive oxygen species.
Ras signal transduction intersects with redox biology, and superoxide has been implicated in modulating Ras-dependent signaling. These observations broaden the process beyond a purely kinase-centric view and suggest context-dependent regulation. Such crosstalk may be relevant to oxidative stress conditions in disease.
Evolutionary conservation of the cassette
In simple terms: The same basic Ras signaling design is found across many organisms.
Ras superfamily GTPases and their signal transduction roles are conserved across eukaryotes, including divergent lineages such as Euglena gracilis. Comparative analyses help define core versus lineage-specific features of the cassette. This conservation supports the use of model systems to study GO:0007265.
Key Genes Involved in GO:0007265 Ras protein signal transduction
The following genes and proteins are central to Ras protein signal transduction (GO:0007265) and are frequently studied in mechanistic and translational research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HRAS | Ras-subfamily GTPase that relays signals when GTP-bound | Classic oncogene and core component of GO:0007265 |
| KRAS | Ras-subfamily GTPase driving MAPK output | Frequently mutated in cancer and a major drug target |
| NRAS | Ras-subfamily GTPase in signal relay | Implicated in oncogenesis and pathway studies |
| RAF1 | RAF kinase effector activated by Ras | Key downstream node and RASopathy gene |
| BRAF | RAF kinase effector in the MAPK cascade | Central to RAS-RAF-MEK-ERK signaling |
| MAP2K1 | MEK kinase downstream of RAF | Effector cascade component in Ras signaling |
| MAPK1 | ERK kinase transmitting signal to substrates | Output node of Ras signal transduction |
| MAPK3 | ERK kinase paralog in the cascade | Output node of Ras signal transduction |
| LZTR1 | Regulator affecting RAS-MAPK signaling | Noonan syndrome-associated gene |
| SOS1 | Guanine nucleotide exchange factor for Ras | Controls Ras activation state |
| NF1 | GTPase-activating protein for Ras | Negative regulator of Ras signaling |
| RASA1 | GTPase-activating protein for Ras | Modulates Ras signal duration |
| PTPN11 | Tyrosine phosphatase influencing RAS-MAPK | RASopathy-associated regulator |
| SHOC2 | Scaffold modulating RAS-MAPK signaling | RASopathy-associated component |
| CBL | Adapter affecting receptor-proximal Ras activation | RASopathy-associated regulator |
| RIT1 | Ras-related GTPase in signaling | RASopathy-associated gene |
| RRAS | Ras-subfamily GTPase | Contributes to Ras-related signal transduction |
How Is Ras protein signal transduction Regulated?
Ras protein signal transduction is regulated primarily at the level of the GTPase cycle, through guanine nucleotide exchange factors that promote GTP loading and GTPase-activating proteins that accelerate hydrolysis. Effector engagement provides a second layer of control, since the duration and intensity of downstream MAPK output depend on which effectors are recruited and for how long. Genetic evidence from RASopathy studies shows that altered regulation of RAS-MAPK signaling, for example through LZTR1, PTPN11, SOS1 or RAF1, can shift pathway output and cause disease. Redox conditions may also modulate Ras-dependent signaling, adding context-dependent regulation. Together, these mechanisms ensure that GO:0007265 is tightly controlled in normal cells.
Ras protein signal transduction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KRAS | Cancer driven by constitutive Ras signaling | Point-mutation knock-in cell model |
| HRAS | Oncogenesis and Ras switch biology | Knockout and overexpression models |
| LZTR1 | Noonan syndrome with enhanced RAS-MAPK signaling | Point-mutation knock-in model |
| PTPN11 | RASopathy-associated signaling dysregulation | Knock-in of disease variants |
| NF1 | Loss of negative regulation of Ras signaling | Knockout model |
Cancer
Deregulated Ras signal transduction is a hallmark of many cancers, where constitutive activation of Ras-subfamily GTPases or downstream effectors drives uncontrolled proliferation. The RAS-RAF-MEK-ERK cascade is a principal oncogenic output, and pathway components are recurrent therapeutic targets. Research into GO:0007265 therefore directly informs oncology drug discovery and resistance studies.
Noonan syndrome and RASopathies
Germline mutations that enhance RAS-MAPK signaling cause developmental RASopathies such as Noonan syndrome. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling. These findings link GO:0007265 directly to human developmental disease and provide genotype-mechanism correlations.
Redox-related pathology
Because Ras signaling intersects with superoxide and redox biology, altered Ras signal transduction may contribute to oxidative stress-related pathology. This connection broadens the disease relevance of GO:0007265 beyond canonical kinase-driven phenotypes. Experimental models that manipulate both Ras activity and redox state can test this crosstalk.
From Ras protein signal transduction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for Ras signal transduction? | CRISPR knockout cell model |
| Does a specific variant alter RAS-MAPK output? | Point-mutation knock-in model |
| Does a disease-associated allele enhance signaling? | Knock-in of patient variants |
| Where does a pathway protein localize? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression mimic oncogenic activation? | Overexpression cell model |
| Which genes modify Ras pathway output? | CRISPR library screening |
How to Study the Ras protein signal transduction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effect on Ras signaling | Causal gene requirement |
| Point-mutation knock-in | Effect of specific variants on pathway output | Variant functional annotation |
| Phospho-ERK immunoblotting | MAPK cascade activation | Pathway activity readout |
| RNA-seq | Transcriptional consequences of Ras signaling | Downstream network analysis |
| Proteomics | Protein-level changes and interactions | Effector and complex analysis |
| GTPase nucleotide assays | GDP/GTP cycling | Switch mechanism studies |
| CRISPR library screening | Genes modifying Ras pathway phenotypes | Modifier discovery |
| Imaging of tagged proteins | Localization and complex assembly | Spatial signaling studies |
Genetic perturbation and pathway readouts
CRISPR knockout, point-mutation and knock-in models allow causal testing of Ras pathway genes, with downstream MAPK phosphorylation used as a readout of signal transduction. These approaches are essential for distinguishing correlation from causation in GO:0007265 research.
Biochemical analysis of the GTPase switch
Biochemical and structural methods measure nucleotide binding, hydrolysis and effector engagement to define how Ras proteins relay signals. Such assays provide mechanistic detail that complements cellular phenotypes.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can capture the downstream consequences of altered Ras signal transduction, including changes in MAPK target gene expression. These global approaches help place GO:0007265 in a broader regulatory network.
Imaging and localization studies
Tagged knock-in and imaging approaches reveal where Ras pathway components localize and how signaling complexes assemble. Localization data are important for understanding effector specificity.
How CRISPR Can Be Used to Study GO:0007265 Ras protein signal transduction
Knockout
CRISPR knockout of Ras pathway genes is used to test whether a component is required for signal transduction and for downstream MAPK output. Loss-of-function models help define the minimal gene set needed for GO:0007265.
Point Mutation
Point-mutation knock-in allows precise testing of disease-associated variants, such as those affecting RAS-MAPK signaling in Noonan syndrome. This approach links specific residues to pathway activity.
Knock-in
Knock-in of tags or reporter sequences enables localization and interaction studies of Ras pathway proteins in their native context. Such models support mechanistic dissection of effector engagement.
Overexpression
Overexpression models are used to mimic activating conditions and to test whether increased dosage of a pathway component enhances Ras signal transduction. They are particularly useful for oncogene-focused studies.
How EDITGENE Supports Ras protein signal transduction Research
Researchers studying Ras protein signal transduction-related genes often need to determine whether a candidate gene is causally involved in pathway output, whether a specific variant alters signaling, or whether dosage changes are sufficient to drive a phenotype. EDITGENE provides the CRISPR cell-model and screening services needed to answer these questions with publication-grade rigor.
Contact EDITGENE today to design your custom CRISPR model for Ras protein signal transduction research.
Frequently Asked Questions About Ras protein signal transduction
What is Ras protein signal transduction?
Ras protein signal transduction (GO:0007265) is an intracellular signaling cassette in which a small monomeric GTPase of the Ras subfamily relays a signal.
What is the GO ID for Ras protein signal transduction?
The Gene Ontology ID is GO:0007265, with the synonym Ras mediated signal transduction.
What genes are involved in Ras protein signal transduction?
Key genes include HRAS, KRAS, NRAS, RAF1, BRAF, MAP2K1, MAPK1, MAPK3, SOS1, NF1 and LZTR1.
How does Ras relay a signal?
Ras cycles between GDP-bound inactive and GTP-bound active states, and GTP-bound Ras engages effectors such as RAF to propagate the signal.
What is the main downstream pathway of Ras?
The best-characterized output is the RAS-RAF-MEK-ERK MAPK cascade.
How is Ras signaling regulated?
It is regulated by guanine nucleotide exchange factors and GTPase-activating proteins that control the GDP/GTP cycle, and by effector engagement.
What diseases are linked to Ras signaling?
Deregulated Ras signaling is linked to cancer and to developmental RASopathies such as Noonan syndrome.
Does Ras signaling involve redox biology?
Yes, Ras signaling has been connected to superoxide and redox-related mechanisms.
How do researchers study Ras protein signal transduction?
Common approaches include CRISPR knockout and knock-in models, phospho-ERK readouts, RNA-seq, proteomics and GTPase assays.
Is Ras signaling conserved across species?
Ras superfamily GTPases and their signaling roles are conserved across eukaryotes, including divergent organisms.
Conclusion
GO:0007265 Ras protein signal transduction defines a central intracellular signaling cassette built on the GTP-dependent Ras switch and its downstream effectors. Its mechanistic core, the RAS-RAF-MEK-ERK cascade, links receptor-proximal cues to proliferation and differentiation programs, and its dysregulation underlies cancer and RASopathies such as Noonan syndrome. Because the pathway is both biologically fundamental and disease-relevant, it remains a priority for CRISPR-based causal studies and therapeutic development.
References
- 1. Jeon H et al.. 2024. Signaling from RAS to RAF: The Molecules and Their Mechanisms.. Annu Rev Biochem 93(1):289-316 PMID: 38316136
- 2. Olson MF et al.. 2000. Ras protein signalling.. Semin Immunol 12(1):63-73 PMID: 10723799
- 3. Field MC. 2024. Ras superfamily GTPases and signal transduction in Euglena gracilis.. Protist 175(2):126017 PMID: 38295671
- 4. Irani K et al.. 1998. Ras, superoxide and signal transduction.. Biochem Pharmacol 55(9):1339-46 PMID: 10076523
- 5. Motta M et al.. 2019. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.. Hum Mol Genet 28(6):1007-1022 PMID: 30481304
- 6. Janowski M. 1991. ras proteins and the ras-related signal transduction pathway.. Radiat Environ Biophys 30(3):185-9 PMID: 1924703
- 7. Wittinghofer A. 1998. Signal transduction via Ras.. Biol Chem 379(8-9):933-7 PMID: 9792425
- 8. Mo SP et al.. 2018. RAS variant signalling.. Biochem Soc Trans 46(5):1325-1332 PMID: 30287508
